Emergent BioSolutions’ rPA anthrax vaccine candidate is a purified recombinant protective antigen protein formulated with an alum adjuvant and is designed to induce antibodies that neutralise anthrax toxins.
Ulipristal acetate, a new oral emergency contraceptive designed and developed by HRA Pharma, has received approval from the European Commission and the Food and Drug Administration in May
The Elixir DESyne BD stent combines a low drug dose (5µg/mm stent length) of internally developed macrocyclic lactone Novolimus, a metabolite of sirolimus and a low polymer load
Emisphere said that the two digestive hormones utilised in the study are released naturally in proportion to ingested calories and signal satiety, or fullness, to the brain. SNAC
Cellectis bioresearch and Helix Biocon aim to promote Cellectis bioresearch’s meganuclease-based products and services in India. Cellectis bioresearch Sales and Marketing VP Luc Selig said that Cellectis bioresearch
Boiron claimed that the launch is a result of the success of Chestal’s counterpart, Children’s Chestal, which was released two years ago amid concerns over the safety of
Healthmed said that Virtual Vantage allows an interface between handheld computers, such as the iPad and stationary computers, and has the capacity to create access the health industry
As per the pact, OctoPlus is expected to develop a controlled release formulation of an undisclosed compound using its proprietary drug delivery technology PolyActive, a biodegradable polymeric drug
The company has posted a operating loss of £6.91m the six months ended 2010, compared to operating loss of £3.61m, for the comparable period in 2009. Silence Therapeutics
ALX-0141 Phase I study is a double-blind, placebo-controlled study designed to assess safety, tolerability and PK of a subcutaneous injection of ALX- 0141. The 120 days follow-up of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.